NEW YORK (GenomeWeb) – After presenting a preliminary analysis last year, researchers have now published in full results from the Phase II SUMMIT trial, which demonstrated how genomically guided basket trials can both expand and contract the eligible population for a drug with important takeaways for larger ongoing studies.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.